Quick Summary
Covering the latest research from top Wall Street investment banks

FDA and EMA approval mechanisms are similar but not fully consistent; EU timing and evidence thresholds may alter the pace of pipeline value realization

Institution
Bernstein
Date
2026-08-14
Authors
Jeffrey Walch, MD, Ph.D., Justin Smith, Courtney Breen, Lee Hambright, Delphine Le Louet, Rebecca Liang, Ph.D., Susannah Ludwig, Miki Sogi, Ph.D., Lance Wilkes, Eve Burstein, Nandan Kulkarni
Company
-
Ticker
-
Industry
Healthcare
Rating
-
NeutralHigh confidenceThe report is an educational overview of regulatory processes and does not provide an explicit investment rating for any specific company or security; its core conclusion is that FDA and EMA approvals overlap substantially but are not fully consistent, and regional differences in regulatory timing and outcomes should be incorporated into pipeline revenue forecasts.
AuthorsJeffrey Walch, MD, Ph.D., Justin Smith, Courtney Breen, Lee Hambright, Delphine Le Louet, Rebecca Liang, Ph.D., Susannah Ludwig, Miki Sogi, Ph.D., Lance Wilkes, Eve Burstein, Nandan Kulkarni
Business segmentsInnovative Drug R&D、Biopharmaceuticals、Rare Disease Treatment、Gene Therapy
Research firm divisions/subsidiariesBernstein(Other)

AI summary card

FDA and EMA approval mechanisms are similar but not fully consistent; EU timing and evidence thresholds may alter the pace of pipeline value realization

Bernstein outlines global innovative-drug approval pathways, advising investors to assess approval probability, review duration, and expedited pathways separately by region rather than equating FDA approval directly with EMA approval.

Thematic research report; no investment rating, target price, or explicit trading recommendation is provided for a single security.
HealthcareInnovative DrugsDrug RegulationFDAEMAClinical TrialsApproval Timing
  • FDA standard review typically takes about 10 months; the EMA centralized procedure has a statutory review period of about 210 days, but this excludes clock stops while companies provide additional information, so the actual process often extends to one year or longer.
  • FDA and EMA approval decisions have historically overlapped substantially, but cases including Aduhelm, Exondys 51, and Leqembi show FDA approvals for products that were not authorized by the EMA or were initially rejected.
  • The FDA has potentially stackable expedited mechanisms including Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review; the EMA's Accelerated Assessment can shorten review from 210 to 150 days.
  • When modeling R&D pipelines, regional filing pathways, the risk of additional-information requests, confirmatory trial obligations, and final launch timing should be incorporated into risk-adjusted revenue forecasts.

Report interpretation

Overview

This report provides a high-level overview of drug regulatory approval processes at the U.S. FDA and the EU EMA, covering regulatory jurisdictions, application types, clinical trial prerequisites, standard review periods, expedited approval mechanisms, and the role of expert committees. The report aims to help investors assess regional regulatory risks and differences in launch timing in future revenue forecasts for drugs in development.

Core views

Both the FDA and EMA focus on drug safety, efficacy, and quality, but differ in organizational structure, documentation requirements, approval pathways, and actual timelines. The FDA implements centralized approval at the federal level in the United States; the EMA coordinates centralized review, while the European Commission issues the final legally binding authorization. FDA approval generally increases the likelihood of EMA approval but provides no guarantee; differences in the assessment of evidentiary sufficiency, clinical benefit, and safety trade-offs can lead to divergent approval outcomes across regions.

Analysis framework

The report uses institutional comparison and case analysis, comparing FDA and EMA filing, review, and expedited pathways, and illustrating the need for region-specific risk adjustment through cases of divergent approvals across agencies; it also references a historical comparison of drug approvals by the two agencies from 2015 to 2025.

Methodology notes

  • Regulatory Comparison FrameworkFDA and EMA Approval Pathway Comparison

    Compares regulatory authority, application types, review processes, and final authorization mechanisms.

    The FDA conducts centralized reviews through CDER and CBER and authorizes products nationwide; the EMA coordinates review through the EU medicines network, after which the European Commission makes the final authorization decision following a CHMP opinion.

  • Risk-Adjusted Revenue ModelingRegional Regulatory Risk Adjustment

    Independently assesses approval probabilities and launch timing by region.

    FDA and EMA outcomes overlap substantially but are not fully consistent, so models should not mechanically extrapolate approval outcomes in one region to another.

  • Approval Timing AnalysisStandard and Expedited Review Timelines

    Incorporates target review durations, clock stops for additional information, and eligibility for expedited pathways into launch forecasts.

    The 210-day EMA centralized procedure excludes clock-stop periods, and the actual timeline may exceed one year; expedited mechanisms can shorten review but carry stringent eligibility requirements or post-marketing study obligations.

Key data

  • FDA Standard Review DurationApproximately 10 monthsA general description applicable to standard applications.
  • EMA Centralized Procedure Standard ReviewApproximately 210 daysExcludes clock stops while applicants respond to questions or provide additional data; the actual process often extends to one year or longer.
  • FDA Priority ReviewApproximately 6 monthsFor applications addressing serious diseases that offer significant improvement over existing treatments.
  • EMA Accelerated Assessment150 daysApplies to medicines of major public health interest representing therapeutic innovation, shorter than the standard 210-day timeline.
  • Comparison of FDA and EMA Approval VolumesFrom 2015 to 2025, FDA approval volumes exceeded EMA approval volumes except in 2016 and 2022The report emphasizes that approval outcomes at the two agencies overlap substantially but are not fully consistent.

Impact & implications

For biopharmaceutical investors, regulatory risk is not only whether a drug is approved, but also the filing region, review clock, additional-information requests, eligible patient population, confirmatory trial obligations after accelerated approval, and cross-regional label differences. A longer or uncertain EMA process may delay European revenue contributions; where safety is contested or evidence of clinical benefit is limited, a favorable FDA decision may not translate into EU commercialization authorization.

Risks

  • Clinical data may be insufficient to demonstrate meaningful clinical benefit, potentially resulting in rejection, restrictions on the eligible patient population, or requirements for additional studies.
  • Safety signals may alter the benefit-risk assessment, particularly for accelerated approvals or controversial indications.
  • Additional-information requests and clock stops during EMA review may materially extend actual launch timelines.
  • The FDA and EMA may weigh evidence for the same drug differently, so approval probabilities across regions are not perfectly correlated.
  • Accelerated or conditional approvals usually carry post-marketing confirmatory trial obligations; failure to complete them or unfavorable results may affect continued authorization.

What to watch

  • The filing sequence and selected approval pathways for pipeline drugs at the FDA and EMA.
  • Whether Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, or EMA Accelerated Assessment designations are obtained.
  • Additional-information requests, clock stops, expert committee discussions, and CHMP opinions during review.
  • Whether clinical endpoints provide direct evidence supporting clinical benefit or rely on surrogate endpoints requiring subsequent confirmation.
  • Whether the FDA and EMA differ in their characterization of safety, the benefit-risk profile, and the target patient population.
Zhejiang ICP No. 2022035445-5
Disclaimer: Market data, charts, indicators, research views, and other information provided on this website are intended solely for information display, research communication, and educational reference. They should not be regarded as personalized investment advice, securities recommendations, trading instructions, solicitations, or guarantees of return. While we strive to improve the reliability of our data and content, such information may still be subject to delays, errors, incompleteness, or untimely updates due to source differences, methodological limitations, system processing, or market volatility. Users should exercise independent judgment based on their own circumstances and bear all risks and responsibilities arising from the use of this website.

Settings

Sign in to view recent logins